Selenium is an essential mineral that plays a key role in plenty of major metabolic processes. A growing body of literature has shown that selenium deficiency leads to an increase in plasma TC and TG levels. This study explores the effect of selenium supplementation on serum level of lipid profile [total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), very low density lipoprotein (VLDL)]. We systematically searched PubMed/MEDLINE, ISI/ WOS, and Scopus (from their commencements to Jan 2016) to identify the papers investigating the association between the intake of selenium and lipid profile. Data extracted from the relevant studies were screened. The pooled standardized mean difference was estimated using the random or fixed effects model. Heterogeneity among the studies was assessed using Q-test. Of the potentially relevant articles screened, 11 articles including 1221 participants were included in this meta-analysis. Results of meta-analysis showed that intake of selenium . This meta-analysis suggests that the effect of selenium supplementation on the serum levels of TG and VLDL is marginally significant. However, the supplementation has no effect on other serum lipids. Moreover, the study shows that the effect of selenium supplementation on lipid profile is negative.
AbStr Ac t
Selenium is an essential mineral that plays a key role in plenty of major metabolic processes. A growing body of literature has shown that selenium deficiency leads to an increase in plasma TC and TG levels. This study explores the effect of selenium supplementation on serum level of lipid profile [total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), very low density lipoprotein (VLDL)]. We systematically searched PubMed/MEDLINE, ISI/ WOS, and Scopus (from their commencements to Jan 2016) to identify the papers investigating the association between the intake of selenium and lipid profile. Data extracted from the relevant studies were screened. The pooled standardized mean difference was estimated using the random or fixed effects model. Heterogeneity among the studies was assessed using Q-test. Of the potentially relevant articles screened, 11 articles including 1221 participants were included in this meta-analysis. Results of meta-analysis showed that intake of selenium resulted in a statistically significant improvement in TC, [ . This meta-analysis suggests that the effect of selenium supplementation on the serum levels of TG and VLDL is marginally significant. However, the supplementation has no effect on other serum lipids. Moreover, the study shows that the effect of selenium supplementation on lipid profile is negative.
Introduction Selenium (Se) is an essential element of many enzymes that have an important role in the activity of glutathioneperoxidase [1] . The necessity of selenoproteins for the survival of mammals has been well documented [2, 3] . The results of available animal trials on the protective effect of selenium supplementation on LDL-R mRNA expression and activity of LDL receptor have been contradictory [4, 5] . It could be associated with regulating apoB and 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase expression [6] . It seems that selenoproteins have a role in cleaning apolipoprotein E (ApoE) and decreasing the serum cholesterol in mice [7] .
The effect of selenium supplementation on a lipid profile in human has remained unclear. Some evidence has shown that deficiency of selenium lead to an increase inplasma total cholesterol (TC) levels [8, 9] . Also, selenium consumption declines total TC and triglyceride (TG) levels [10, 11] . In contrast, some cross-sectional studies have reported that higher levels of serum level are associated with higher serum cholesterol, TG, and LDL [12] [13] [14] . Recent findings on the association of the supplementation with selenium on lipid profile have been non-conclusive. A 7.5-year clinical trial on the supplementation with 100 μg selenium per day found a rise in the serum lipid of the intervention group [15] . Another clinical trial with high-selenium yeast indicated a modestly beneficial effect the lipid profile of the subjects with low serum levels of selenium [16] . Recently Tabrizi et al. conducted a systematic review and meta-analysis on patients with metabolic diseases and the results showed positive effects of selenium supplementation on lipid profiles [17] . However, to the best of our knowledge, no comprehensive meta-analysis has been carried out on the effect of selenium supplement on lipid profile in all type of diseases. Available reviews have investigated the selenium effects on cardiovascular endpoints or metabolic diseases in human studies. The current systematic review and meta-analysis was aimed to assess effect of selenium supplementation on lipid profile including total cholesterol, triglyceride, low-density lipoproteins, and high-density lipoproteins in various diseases and disorders.
Methods
This review is an attempt to investigate the probable effects of selenium supplementation on lipid profile. Based on the study protocol, all relevant papers were screened [18, 19] . The method of screening is discussed in more detail in our previous paper [20] .
Search strategy
We searched the international databases of PubMed, ISI/WOS, and Scopus for the studies on the probable effects of selenium supplementation on lipid profile in 2016. The key terms for searching the data sources were "lipid profile" and "Selenium supplementation". We only included the published articles in English. We did not limit our search by time or the year of publications. Gray literature and key journals were searched for additional data.
Inclusion and exclusion criteria
We included all RCT and cross-over trails, which control group received the placebo, irrespective of date and language. For RCTs, where there was no interaction with Se consumption and access to the study objectives, all studies in different target groups comprising diabetic patients, PCOS subjects, obese subjects, or even healthy individuals were included. We included those studies in which selenium was used as a single therapy or in a combination therapy. All studies were included in which Se was prescribed for therapeutic procedures (such as anti-angiogenic and anti-metastatic agents for cancer treatment).
A three-stage process of screenig were used to evaluate the aticles. The titles , abstracts, and the full texts were scrutinized for inclusion by two independent investigators. Possible disagreements were resolved by a third investigator. All studies associated with articles and meta-analyses evaluated to review their references. If there were more than one paper that were extracted by one specific study, the most complete reported data were only considered by one paper. We also excluded article with a duplicate citation and those, based on data refinement results are non-relevant. There was no time limit on the study, the duration of Se supplementation, language of documents, or time of publication.
Outcomes and intervention
Outcomes investigated in studies were the effect of selenium supplementation on lipid profiles such as cholesterol, TG, LDL, HDL, VLDL, HDL/TC, and non-HDL-C. The type of intervention was intended to be oral supplemental selenium and with any doses.
Quality assessment and data extraction
The quality assessment and data extraction of eligible papers were conducted by two independent research experts [20] . Data (i. e., the citation information, the details of study design, the year of publication, the dose of supplementation, intervention group, control group, mean age of the participants, outcomes, intervention duration, follow up information, measurements and result and effect size) were extracted using a data extraction sheet.
Statistical analysis and data synthesis
Q-test and I 2 were used for assessing heterogeneity among the studies. We used random-effects model when the Q-statistic for heterogeneity was significant at the level of 0.1, [21] . In other cases, the fixed-effects model was used [22] . The degree of heterogeneity was quantified using I 2 statistics. The I 2 statistics shows that the total variation across studies is related to heterogeneity [23, 24] . I 2 values of 25 %, 50 % and 75 % were considered to correspond to low, medium, and high levels of heterogeneity, respectively. Possible sources of heterogeneity were explored by sensitivity analysis. Random or fixed effects meta-analysis was used to estimate pooled SMD and 95 % confidence interval (CI). Meta-analysis was performed to examine the association of selenium supplementation with each lipid profile. The forest plot was used to present the pooled SMD and its 95 % confidence interval (CI) schematically. To evaluate the association of estimated SMD and potential confounders such as the dose of selenium supplementation, the duration of intervention, mean age and sex ratio, random-effects meta-regression was performed. Publication bias was assessed using Egger's tests and the results of Egger's test were considered statistically significant at p < 0.1. The results of publication bias were presented schematically using the funnel plot.
This study was based on the following assumption: The effects of Se intervention on all lipid profiles are negative while its effect on high-density lipoprotein (HDL) is positive. To analyze the overall effect, we multiplied HDL's SMDs by a negative factor. The statistical analysis was carried out using STATA software, version 11 [25] . A p-value ≤ 0.05 was considered statistically significant.
Results

Search results and characteristics of included studies
Flow chart 1 (▶ Fig. 1 ) summarizes the study screening processes. According to the inclusion/exclusion criterion, 11 articles were eligible to be included in this meta-analysis [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . The characteristics of these studies are detailed in ▶ table 1.
All of 11 studies (9 randomized controlled trials, 1 quasi-experimental, and 1 crossover) were published between 2007 and 2016. Two studies did not meet the criteria of RCT and were not analyzed [29, 30] . All RCTs randomly assigned a total of 614 participants to the intervention groups and 607 participants to the control groups. The age of the patients ranged from 10 to 85 years. Eight studies recruited both men and women and in other three RCTs only female subjects were enrolled. Three trials used selenium in a combination with other vitamins or minerals [27, 28, 31] , and 8 trials used selenium alone [26, [32] [33] [34] [35] [36] . The daily dose of selenium varied in the various trials. Six RCTs used 200 μg/day selenium supplementation [26, 28, [32] [33] [34] [35] , one RCT used 100 μg/day [27] and one RCT used 50 μg/day [28] . The study by Cold et al. [36] was con▶Fig. 1 Flow chart of the number of studies selected for the meta-analysis. sidered as three studies because three different groups received three different doses (100, 200, 300 μg/day) [36] . All supplementations were administered orally. All trials were placebo-controlled, and all were double-blinded. The intervention periods ranged from 42 days [26] to 180 days [36] .
Of the 11 studies, 8 of them studied people with various diseases, and 3 studied healthy subjects. Selected studies enrolled the subjects with GDM [26] , the patients with at least two cardiovascular risk factors [27] , the premenopausal women with central obesity [28] , the obese children and adolescents [31] , type 2 diabetes [33, 34] , PCOS patients [32] , patients with CHD [34] , diabetic nephropathy [35] .
Meta-analysis
All of 11 articles with 1221 participants on selenium or placebo groups investigated TC and 8 RCTs examined TG, LDL, and HDL as the outcome at baseline and follow-up. In addition to these factors, 3 studies also evaluated VLDL, 4 studies evaluated HDL/TC ratio and 3 studies evaluated Non-HDL-C as the outcome. These results are shown in ▶table 2.
The selenium supplementation did not significantly improve the lipid profiles such as LDL [pooled standardized mean difference The result of the test for overall effect using the fixed-effects model is shown in ▶Fig. 2. Meta-analyses suggested that selenium supplementation resulted in no significant improvement in lipid profile compared with placebo [SMD: -0.033, 95 % CI: -0.08, 0.02].
Quality assessment
The quality of the included studies is shown in ▶table 3. Eight studies were classified as high quality. The CONSORT scores of these paper were higher than 30 [26, 28, 32, [34] [35] [36] , three studies were of medium quality according to CONSORT scores (in the range of 25-30) [27, 31, 33] , and two studies with CONSORT scores lower than 25 were classified as low quality [29, 30] . Randomization as a prerequisite for inclusion in this meta-analysis was conducted in 8 studies.
All 11 RCTs were double-blind [26] [27] [28] [31] [32] [33] [34] [35] [36] , but only two studies were described blinding [32, 34] .
Subgroup analysis
Clinical trials were divided into two subgroups according to participants (healthy and unhealthy participants). Of the 11 studies, 8 of them studied people with various diseases, and 3 studied healthy people. Our results from the lipid profile analysis showed that the effect of selenium supplementation in decreasing the level of TC and increasing the level of HDL and HDL/TC in healthy participants remained significant but in the unhealthy 4F patients lost its significance.
Meta-regression
The effect of influencing factors was analyzed using the random-effects meta-regression model. The present study found that factors such as duration (coefficient = -0.001, p = 0.74), mean age (coefficient = 0.0006, p = 0.94), dose (coefficient = -0.001, p = 0.79), lipid profile (coefficient = 0.014, p = 0.69) and female ratio (coefficient = -0.005, p = 0.31), have no effect on the heterogeneity (p > 0.05).
Sensitivity analysis
According to a study done by Cold et al. [36] , sensitivity analysis can considerably change the effect of selenium supplementation on the level of total cholesterol to no significant result [(SMD): -0.04, 95 % CI: (-0.16, 0.09)]. Also, the omission of any of the studies carried out by Jamilian [32] [(SMD): -0.21, 95 % CI: (-0.57, 0.14)] and Bahmani [35] [(SMD): -0.32, 95 % CI: (-0.67, 0.02)] could change the result and cause non-significant effects of selenium supplementation on VLDL levels. Sensitivity analysis could not show considerable change regarding the effect of selenium supplementation on the level of HDL, LDL, HDL/TC, and non-HDL-C after excluding any of the studies. 
Publication bias
Discussion
This study was conducted to investigate the effect of selenium supplementation on lipid profile in various type of diseases. The meta-analysis of 11 RCT papers showed that the supplementation with selenium did not have any effect on total TC, LDL, and HDL. It was found that that selenium supplementation decreased TG and VLDL. Although there was no heterogeneity among studies used in this meta-analysis on the effect of selenium consumption on TG level, this effect was less than one unit. Only three studies on the effect of selenium on VLDL were eligible for our meta-analysis A 7.5-year study on the rural elderly reported that compared with those in the lowest quintile of serum selenium, the subjects in the highest quartile of selenium had a significant decrease in total TC and TG but an increase in HDL [37] .
A randomized, placebo-controlled, parallel-group study stratified by age and sex in 2011 reported that high selenium-yeast supplementation was effective not only in decreasing total TC and LDL serum levels but also in increasing HDL level [38] .
In another study, selenium supplementation among the subjects with diabetes resulted in deterioration of blood glucose homeostasis. However, this study indicated that selenium supplementation improved the HDL level [39] .
Some cross-sectional studies have reported that higher serum level of selenium may be associated with an adverse blood lipid profile. A cross-sectional study in Britain in 2010 reported that higher plasma selenium was associated with an increase in TC and non-HDL levels but not with HDL [40] . Another study among the rural Chinese population indicated that the highest quintile of serum selenium level resulted in higher LDL-C and higher TC. In the strati▶table 2 Meta-analysis of effects of selenium supplementation on lipid profile.
Lipid profile
Group ( a Two studies did not meet the criteria of RCT and were not analyzed.; b Assessment of two studies on the effects of selenium supplementation on total-/ HDL-cholesterol ratio as outcome was not included in meta-analysis.; * Statistically significant.; c In one study, three different doses of adiponectin were used and was considered as three studies.
fied analyses, the authors found that the higher serum selenium increased odds ratio for dyslipidemia of 2.76 among the postmenopausal women and odds ratio of 9.4 in the subjects with diabetes [41] . A double-blinded randomized clinical trial which lasted for 3 months revealed that the selenium consumption was not effective in changing the lipid profile of hemodialysis patients [42] .
In contrast, a cross-sectional study in 2008 on 5452 men and women in the US demonstrated that there was a dose dependent direct association between the serum selenium level and lipid profile [43] .
Also our results are in line with Tabrizi's et al. Although our study is more comprehensive than their study, the reason for not seeing the effect on some factors in our study can be that the number of articles and type of disease are different and Tabrizi and his colleagues have only worked on metabolic patients as reported in 5 articles [17] .
It seems that there is a huge discrepancy in results of studies that assessed the association between serum selenium intake and lipid profile. Selenium is a crucial component of lipid metabolism. Selenium is a crucial component of glutathione peroxidases. These enzymes have an important role in lipid metabolism. Moreover, the selenium is crucial for human normal development and growth, fertility in men, and thyroid hormone metabolism [44] .
The strength of our study is that it is the first study to be done on various type of diseases. It is possible that some of the limita- * Cross-over design, * * Quasi-experimental study.
(1a) Identification as a randomized trial in the title. tions could have influenced the results of the study. First, this study included only the research published in English language. Second, because of the scarcity of the data, we could not perform subgroup analysis on the effect of selenium supplementation on the subjects with insufficient and sufficient levels of selenium and we did not examine how this relation could have been affected by the ethnicity of the subjects. Further double blind clinical trials with large sample size should be carried out to quantify these effects more precisely. Participants in future studies need to be stratified in terms of baseline levels of selenium and they can be recruited from different ethnic groups.
Conclusion
This meta-analysis suggests that the effect of selenium supplementation on the serum levels of TG and VLDL is marginally significant. However, the supplementation has no effect on other serum lipids. Moreover, in contrast to some clinical trials results, the study shows that the effect of selenium supplementation on lipid profile is negative. (5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered.
(14a) Dates defining the periods of recruitment and follow-up.
(6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed.
(14b) Why the trial ended or was stopped.
(6b) Any changes to trial outcomes after the trial commenced, with reasons.
(15) A table showing baseline demographic and clinical characteristics for each group.
(7a) How sample size was determined.
(16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups.
(7b) When applicable, explanation of any interim analyses and stopping guidelines.
(17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95 % confidence interval) (8a) Method used to generate the random allocation sequence.
(17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended.
(8b) Type of randomization; details of any restriction (such as blocking and block size).
(18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory.
(9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned.
(19) All important harms or unintended effects in each group (for specific guidance see CONSORT for harms).
(10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions.
(20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses.
(11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how. (13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analyzed for the primary outcome.
(25) Sources of funding and other support (such as supply of drugs), role of funders.
(13b) For each group, losses and exclusions after randomization, together with reasons.
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